Salīdzināt metodes
Apskatiet izvēlētās metodes blakus; rindas, kas atšķiras, ir izceltas.
| Farmakokinētiskais kompartmentu modelis× | Farmakokinētika populācijā× | |
|---|---|---|
| Nozare | Farmakometrija | Farmakometrija |
| Saime | Regression model | Regression model |
| Izcelsmes gads≠ | 1982 | 1977 |
| Autors≠ | Gibaldi & Perrier | Sheiner, Rosenberg & Marathe |
| Tips≠ | Deterministic ODE-based pharmacokinetic model | Nonlinear mixed-effects regression model |
| Pirmavots≠ | Gibaldi, M., & Perrier, D. (1982). Pharmacokinetics (2nd ed.). Marcel Dekker. ISBN: 978-0-8247-1042-2 | Sheiner, L. B., Rosenberg, B., & Marathe, V. V. (1977). Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics, 5(5), 445–479. DOI ↗ |
| Citi nosaukumi | Mammillary Compartment Model, Multi-Compartment PK Model, Compartmental Analysis, Farmakokinetik Kompartman Modeli | PopPK, Nonlinear Mixed-Effects Modeling, NONMEM Approach, Popülasyon Farmakokinetiği |
| Saistītās≠ | 3 | 2 |
| Kopsavilkums≠ | The pharmacokinetic compartment model represents the body as one or more hypothetical compartments interconnected by first-order rate processes, describing how a drug is absorbed, distributed, and eliminated over time. Systematized by Gibaldi and Perrier in 1982, these models use ordinary differential equations to characterize plasma concentration-time profiles. They are the cornerstone of drug development, dosage regimen design, and regulatory submission pharmacokinetic analyses. | Population Pharmacokinetics (PopPK) is a nonlinear mixed-effects modeling framework that characterizes how drugs are absorbed, distributed, metabolized, and eliminated across a patient population, estimating both typical population parameters and the magnitude of between-subject variability. Introduced by Sheiner, Rosenberg, and Marathe in 1977, it enables parameter estimation from sparse, routinely collected clinical data—making it indispensable in drug development, regulatory submissions, and individualized dosing. |
| ScholarGateDatu kopa ↗ |
|
|